| Serial Number | 98350601 |
| Word Mark | ARZZELIOS |
| Filing Date | Wednesday, January 10, 2024 |
| Status | 688 - NOTICE OF ALLOWANCE - ISSUED |
| Status Date | Tuesday, October 22, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, August 27, 2024 |
| Goods and Services | Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for the treatment and prevention of cravings for opioid substances or opiate substances; Pharmaceutical preparations for the treatment and prevention of nausea; Pharmaceutical preparations for the treatment and prevention of vomiting; Pharmaceutical preparations for the treatment and prevention of substance dependence; Pharmaceutical preparations for the treatment and prevention of anxiety; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by an over-expression of the neuropeptide known as substance P; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by overstimulation of the neurokinin-1 (NK-1) receptor; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for the treatment of bipolar disorder; Pharmaceutical preparations for the treatment of schizophrenia; Pharmaceutical preparations for the treatment of bile acid diarrhea; Pharmaceutical preparations for the treatment of tyrosine kinase inhibitor (TKI)-induced diarrhea; Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of COVID-19; Pharmaceutical preparations for the treatment of inflammatory lung injury (ILI); Pharmaceutical preparations for the treatment of acute respiratory distress syndrome (ARDS); Pharmaceutical preparations for the treatment of social anxiety disorder; Pharmaceutical preparations for the treatment of performance anxiety; Pharmaceutical preparations for the treatment of public speaking anxiety; Pharmaceutical preparations for the treatment of circadian rhythm disorders; Pharmaceutical preparations for the treatment of jet lag disorder; Pharmaceutical preparations for the treatment of insomnia; Pharmaceutical preparations for the treatment of Delayed Sleep Phase Disorder (DSPD); Pharmaceutical preparations for the treatment of non-24 hour sleep-wake disorder; Pharmaceutical preparations for the treatment of Smith-Magenis Syndome; Pharmaceutical preparations for the treatment of nighttime sleep disturbances in patients with Smith-Magenis Syndrome (SMS); Pharmaceutical preparations for the treatment of major depressive disorder (MDD); Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of multiple myeloma; Pharmaceutical preparations for the treatment of Charcot-Marie-Tooth disease; Pharmaceutical preparations for the treatment of hematologic malignancies; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, January 10, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Vanda Pharmaceuticals Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Washington, DC 20037 |
| Party Name | Vanda Pharmaceuticals Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Washington, DC 20037 |
| Event Date | Event Description |
| Wednesday, January 10, 2024 | NEW APPLICATION ENTERED |
| Monday, April 29, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, May 9, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, May 9, 2024 | NON-FINAL ACTION WRITTEN |
| Thursday, May 9, 2024 | NON-FINAL ACTION E-MAILED |
| Thursday, May 9, 2024 | ASSIGNED TO EXAMINER |
| Wednesday, July 24, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, July 24, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, July 24, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, July 25, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, August 7, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, August 27, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, August 27, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, October 22, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |